238 related articles for article (PubMed ID: 25254649)
21. Mitochondria-targeting multifunctional nanoplatform for cascade phototherapy and hypoxia-activated chemotherapy.
Lv J; Wang S; Qiao D; Lin Y; Hu S; Li M
J Nanobiotechnology; 2022 Jan; 20(1):42. PubMed ID: 35062959
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
23. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
Sun JD; Liu Q; Ahluwalia D; Li W; Meng F; Wang Y; Bhupathi D; Ruprell AS; Hart CP
Cancer Biol Ther; 2015; 16(3):438-49. PubMed ID: 25679067
[TBL] [Abstract][Full Text] [Related]
25. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
[TBL] [Abstract][Full Text] [Related]
26. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
Hu J; Handisides DR; Van Valckenborgh E; De Raeve H; Menu E; Vande Broek I; Liu Q; Sun JD; Van Camp B; Hart CP; Vanderkerken K
Blood; 2010 Sep; 116(9):1524-7. PubMed ID: 20530289
[TBL] [Abstract][Full Text] [Related]
27. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
[TBL] [Abstract][Full Text] [Related]
28. Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302.
Wojtkowiak JW; Cornnell HC; Matsumoto S; Saito K; Takakusagi Y; Dutta P; Kim M; Zhang X; Leos R; Bailey KM; Martinez G; Lloyd MC; Weber C; Mitchell JB; Lynch RM; Baker AF; Gatenby RA; Rejniak KA; Hart C; Krishna MC; Gillies RJ
Cancer Metab; 2015; 3(1):2. PubMed ID: 25635223
[TBL] [Abstract][Full Text] [Related]
29. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
30. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.
Liapis V; Labrinidis A; Zinonos I; Hay S; Ponomarev V; Panagopoulos V; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
Cancer Lett; 2015 Feb; 357(1):160-169. PubMed ID: 25444931
[TBL] [Abstract][Full Text] [Related]
32. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
Liu Q; Sun JD; Wang J; Ahluwalia D; Baker AF; Cranmer LD; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1487-98. PubMed ID: 22382881
[TBL] [Abstract][Full Text] [Related]
33. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
Saggar JK; Tannock IF
Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
[TBL] [Abstract][Full Text] [Related]
34. Evofosfamide, a new horizon in the treatment of pancreatic cancer.
Pourmorteza M; Rahman ZU; Young M
Anticancer Drugs; 2016 Sep; 27(8):723-5. PubMed ID: 27232101
[TBL] [Abstract][Full Text] [Related]
35. Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer.
Anderson RF; Li D; Hunter FW
Free Radic Biol Med; 2017 Dec; 113():564-570. PubMed ID: 29111232
[TBL] [Abstract][Full Text] [Related]
36. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer.
Haynes J; McKee TD; Haller A; Wang Y; Leung C; Gendoo DMA; Lima-Fernandes E; Kreso A; Wolman R; Szentgyorgyi E; Vines DC; Haibe-Kains B; Wouters BG; Metser U; Jaffray DA; Smith M; O'Brien CA
Clin Cancer Res; 2018 May; 24(9):2116-2127. PubMed ID: 29476017
[No Abstract] [Full Text] [Related]
37. Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104.
Cairns RA; Bennewith KL; Graves EE; Giaccia AJ; Chang DT; Denko NC
Clin Cancer Res; 2009 Dec; 15(23):7170-4. PubMed ID: 19920111
[TBL] [Abstract][Full Text] [Related]
38. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
[TBL] [Abstract][Full Text] [Related]
39. EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate.
Matsumoto S; Saito K; Yasui H; Morris HD; Munasinghe JP; Lizak M; Merkle H; Ardenkjaer-Larsen JH; Choudhuri R; Devasahayam N; Subramanian S; Koretsky AP; Mitchell JB; Krishna MC
Magn Reson Med; 2013 May; 69(5):1443-50. PubMed ID: 22692861
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
Gerard Y; Voissière A; Peyrode C; Galmier MJ; Maubert E; Ghedira D; Tarrit S; Gaumet V; Canitrot D; Miot-Noirault E; Chezal JM; Weber V
Bioorg Chem; 2020 May; 98():103747. PubMed ID: 32208207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
